Hey, I hop on the call a little bit late, I'm traveling.
Aug 5, 2025 / receipt, needs a key / David Larson, other | earnings call 2025-08-05 | transcript ea128963-5f2d-4b0a-bc7f-771a09b0b924 | chars 32682-32738 | segment 33
But those opportunities are still in play. They've been pushed to a degree because of COVID-related restrictions on travel as it relates to validating and qualifying given facilities to support that work.
May 4, 2021 / receipt, needs a key / Jerry, CEO | earnings call 2021-05-04 | transcript e9af0ed5-bbce-4943-b7d8-3f6bdffed297 | chars 16267-16471 | segment 16
$192-$196M +9-11% Organic Growth FY2026 Updated Revenue Guidance
ir_statement / Sep 15, 2026 / receipt
($0.6M) $2.2M Improvement YoY Q1 FY2026 Adjusted EBITDA
ir_statement / Sep 15, 2026 / receipt
$192-$196M +9-11% Organic Growth FY2026 Updated Revenue Guidance
ir_statement / Sep 15, 2026 / receipt
Cryoport’s plans to complete these adjustments by the year’s end and Cryoport’s belief that these measures will lead to a return to positive adjusted EBITDA during 2025
ir_statement / Sep 14, 2026 / receipt
difficulties, delays or Cryoport’s inability to successfully complete it’s planned cost reduction and capital realignment measures
ir_statement / Sep 14, 2026 / receipt
$192-$196M +9-11% Organic Growth FY2026 Updated Revenue Guidance
ir_statement / Sep 14, 2026 / receipt
($0.6M) $2.2M Improvement YoY Q1 FY2026 Adjusted EBITDA
ir_statement / Sep 14, 2026 / receipt
Currently forecasting up to 10 additional BLA / MAA filings and 8 new therapy approvals in 2026
ir_statement / Sep 13, 2026 / receipt
Remains focused on scaling its services to meet the needs of the patient population growth
ir_statement / Sep 13, 2026 / receipt
The Company continues to introduce capabilities to its existing clients and adds new clients to its global network
ir_statement / Sep 13, 2026 / receipt
The patient population for CGTs is projected to grow significantly as more treatments are approved
ir_statement / Sep 13, 2026 / receipt
Growing Clinical Trial Count
ir_statement / Sep 13, 2026 / receipt
| Gerald Shelton | CEO | - | receipt |
| Jerrell W. Shelton | President and Chief Executive Officer | - | receipt |
| Mark Englehart | Chief Commercial Officer | - | receipt |
| Mark Sawicki | CSO | - | receipt |
| Michael Bartholomew | Chief Commercialization Officer | - | receipt |
| Ram Jagannath | director | - | receipt |
| Richard G. Rathmann | Chairman of the Board | - | receipt |
| Robert S. Stefanovich | Chief Financial Officer | - | receipt |
| Robert Stavanovic | Chief Financial Officer | - | receipt |
| Steven Leatherman | Chief Commercial Officer | - | receipt |
| 2020-10-01 | director, appointed | sec_8k |
| 2013-09-10 | Chairman of the Board, appointed | sec_8k |
| 2012-11-06 | President and Chief Executive Officer, appointed | sec_8k |
| 2012-04-10 | Chief Executive Officer, departed | sec_8k |
| 2012-04-06 | Chief Commercial Officer, appointed | sec_8k |
| 2011-06-28 | Chief Financial Officer, appointed | sec_8k |
| 2011-04-07 | Chief Commercial Officer, appointed | sec_8k |
| 2010-09-16 | Chief Commercialization Officer, appointed | sec_8k |